<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002060075</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001815442</issuerCik>
<issuerName>KYMERA THERAPEUTICS, INC.</issuerName>
<secFileNumber>001-39460</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">500 North Beacon Street</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">4th Floor</street2>
<city xmlns="http://www.sec.gov/edgar/common">Watertown</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02472</zipCode>
</issuerAddress>
<issuerContactPhone>(857)-285-5300</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Noah Goodman</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Officer</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Morgan Stanley Smith Barney LLC</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">1 New York Plaza</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">38th Floor</street2>
<city xmlns="http://www.sec.gov/edgar/common">New York</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10004</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>11611</noOfUnitsSold>
<aggregateMarketValue>1014221</aggregateMarketValue>
<noOfUnitsOutstanding>81642394</noOfUnitsOutstanding>
<approxSaleDate>04/09/2026</approxSaleDate>
<securitiesExchangeName>NASDAQ</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>04/09/2026</acquiredDate>
<natureOfAcquisitionTransaction>Shares acquired upon vesting of Restricted Stock Units awarded under the Issuer's 2020 Equity Incentive Plan.</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>KYMERA THERAPEUTICS, INC.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>9111</amountOfSecuritiesAcquired>
<paymentDate>04/09/2026</paymentDate>
<natureOfPayment>Equity compensation</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>04/09/2026</acquiredDate>
<natureOfAcquisitionTransaction>Exercise of Stock Options</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>KYMERA THERAPEUTICS, INC.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>2500</amountOfSecuritiesAcquired>
<paymentDate>04/09/2026</paymentDate>
<natureOfPayment>Cash</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<remarks>The securities to be sold were acquired upon the vesting of restricted stock units on 4/8/2026 or were received upon the exercise of stock options. The dates of acquisition and payment were and will be the dates of exercise/sale.
Certain sales reported on this Form 144 represent shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are automatic and intended to qualify under Rule 10b5-1. Other sales are pursuant to a 10b5-1 plan entered into on December 10, 2025.</remarks>
<noticeSignature>
<noticeDate>04/09/2026</noticeDate>
<signature>/s/ Bruce Jacobs</signature>
</noticeSignature>
</formData>
</edgarSubmission>
